Javascript must be enabled to continue!
Evaluation of glycemic status and subclinical atherosclerosis in familial hypercholesterolemia subjects with or without LDL receptor mutation
View through CrossRef
Abstract
Background
Familial hypercholesterolemia (FH) is a genetic condition characterized by elevated LDL-C and increased cardiovascular risk. Beyond LDL-C levels, the impact of genotype on glucose homeostasis has not been well evaluated. We aimed to evaluate the impact of genotype on glycemic status and on atherosclerotic injury in FH subjects.
Methods
We conducted a cross-sectional study on 322 FH subjects not on lipid-lowering therapy and without history of cardiovascular disease. Biochemical and genetic analyses as well as vascular profile assessment were obtained from all subjects. The study population was divided into two groups according to genotype: LDL receptor (LDLR) group and non-LDLR (NLDLR) group.
Results
The LDLR group exhibited a higher prevalence of low glycemic status (LGS) than the NLDLR group (44.1% vs. 26%, p < 0.01), whereas a high glycemic status (HGS) was more prevalent in the NLDLR group compared with LDLR group (74% vs. 55.9%, p < 0.01). The NLDLR group exhibited a higher prevalence of peripheral atherosclerotic plaques than the LDLR group (93.4% vs. 73%, p < 0.05), while coronary artery calcification (CAC) presence was more prevalent in the LDLR group compared with the NLDLR group (74.7% vs. 48%, p < 0.01). In a secondary analysis the study population was stratified into three groups based on LDLR genotype: NLDLR, LDLR defective, LDLR null groups. The prevalence of LGS progressively increased from the NLDLR to the LDLR null group, while HGS showed an inverse trend (p for trend < 0.05). Peripheral atherosclerotic plaque prevalence decreased from the NLDLR to the LDLR null group (p for trend < 0.05), while CAC prevalence increased progressively in the three groups (p for trend < 0.01). Logistic regression analysis showed that FH groups with an LDLR mutation were inversely associated with HGS (p for both < 0.01) and the LDLR null group exhibited the strongest association.
Conclusions
FH subjects with NLDLR mutations exhibited a worse glycemic profile, while null LDLR mutations showed the strongest inverse association with HGS. The integrations of genetic, lipid and glucose data could be useful to better identify the metabolic profile and the atherosclerosis distribution in FH subjects.
Graphical abstract
Research insights
What is currently known about this topic?
Familial hypercholesterolemia (FH) is characterized by elevated LDL-C levels. LDLR null mutations protected pancreatic β-cells from cholesterol accumulation. NGS has improved FH diagnosis by analysis of all genes implicated in the lipid disorder.
What is the key research question?
What is the impact of FH genotype (monogenic with or without LDLR mutation/polygenic) on glycemic status?
What is new?
FH population was characterized by a heterogeneous glycemic profile according to LDLR mutation. LDL-C and plasma glucose could modulate the distribution of subclinical atherosclerosis.
How might this studyinfluence clinical practice?
Genetic, lipid, glucose data could better identify the metabolic and atherosclerotic profiles in FH.
Springer Science and Business Media LLC
Title: Evaluation of glycemic status and subclinical atherosclerosis in familial hypercholesterolemia subjects with or without LDL receptor mutation
Description:
Abstract
Background
Familial hypercholesterolemia (FH) is a genetic condition characterized by elevated LDL-C and increased cardiovascular risk.
Beyond LDL-C levels, the impact of genotype on glucose homeostasis has not been well evaluated.
We aimed to evaluate the impact of genotype on glycemic status and on atherosclerotic injury in FH subjects.
Methods
We conducted a cross-sectional study on 322 FH subjects not on lipid-lowering therapy and without history of cardiovascular disease.
Biochemical and genetic analyses as well as vascular profile assessment were obtained from all subjects.
The study population was divided into two groups according to genotype: LDL receptor (LDLR) group and non-LDLR (NLDLR) group.
Results
The LDLR group exhibited a higher prevalence of low glycemic status (LGS) than the NLDLR group (44.
1% vs.
26%, p < 0.
01), whereas a high glycemic status (HGS) was more prevalent in the NLDLR group compared with LDLR group (74% vs.
55.
9%, p < 0.
01).
The NLDLR group exhibited a higher prevalence of peripheral atherosclerotic plaques than the LDLR group (93.
4% vs.
73%, p < 0.
05), while coronary artery calcification (CAC) presence was more prevalent in the LDLR group compared with the NLDLR group (74.
7% vs.
48%, p < 0.
01).
In a secondary analysis the study population was stratified into three groups based on LDLR genotype: NLDLR, LDLR defective, LDLR null groups.
The prevalence of LGS progressively increased from the NLDLR to the LDLR null group, while HGS showed an inverse trend (p for trend < 0.
05).
Peripheral atherosclerotic plaque prevalence decreased from the NLDLR to the LDLR null group (p for trend < 0.
05), while CAC prevalence increased progressively in the three groups (p for trend < 0.
01).
Logistic regression analysis showed that FH groups with an LDLR mutation were inversely associated with HGS (p for both < 0.
01) and the LDLR null group exhibited the strongest association.
Conclusions
FH subjects with NLDLR mutations exhibited a worse glycemic profile, while null LDLR mutations showed the strongest inverse association with HGS.
The integrations of genetic, lipid and glucose data could be useful to better identify the metabolic profile and the atherosclerosis distribution in FH subjects.
Graphical abstract
Research insights
What is currently known about this topic?
Familial hypercholesterolemia (FH) is characterized by elevated LDL-C levels.
LDLR null mutations protected pancreatic β-cells from cholesterol accumulation.
NGS has improved FH diagnosis by analysis of all genes implicated in the lipid disorder.
What is the key research question?
What is the impact of FH genotype (monogenic with or without LDLR mutation/polygenic) on glycemic status?
What is new?
FH population was characterized by a heterogeneous glycemic profile according to LDLR mutation.
LDL-C and plasma glucose could modulate the distribution of subclinical atherosclerosis.
How might this studyinfluence clinical practice?
Genetic, lipid, glucose data could better identify the metabolic and atherosclerotic profiles in FH.
Related Results
A-231 A modified Sampson LDL-C equation to improve concordance with the reference method at low levels of LDL-C
A-231 A modified Sampson LDL-C equation to improve concordance with the reference method at low levels of LDL-C
Abstract
Background
Patients at high risk for Atherosclerotic Cardiovascular Disease (ASCVD), who do not achieve adequate loweri...
Developing a Modified Low-Density Lipoprotein (M-LDL-C) Friedewald’s Equation as a Substitute for Direct LDL-C Measure in a Ghanaian Population: A Comparative Study
Developing a Modified Low-Density Lipoprotein (M-LDL-C) Friedewald’s Equation as a Substitute for Direct LDL-C Measure in a Ghanaian Population: A Comparative Study
Despite the availability of several homogenous LDL-C assays, calculated Friedewald’s LDL-C equation remains the widely used formula in clinical practice. Several novel formulas dev...
An improved method for estimating low LDL-C based on the enhanced Sampson-NIH equation
An improved method for estimating low LDL-C based on the enhanced Sampson-NIH equation
Abstract
Background
The accurate measurement of Low-density lipoprotein cholesterol (LDL-C) is critical in the decision to utilize the new lipid-low...
LDL-C reduction and residual cardiovascular risk in heterozygous familial hypercholesterolemia: a matched cohort study in South Wales
LDL-C reduction and residual cardiovascular risk in heterozygous familial hypercholesterolemia: a matched cohort study in South Wales
Abstract
Background
Heterozygous familial hypercholesterolemia (HeFH) is characterized by lifelong elevated LDL-C and inc...
PCSK-9 Inhibitors
PCSK-9 Inhibitors
Hyperlipidemia (elevated levels of LDL-C) is a well-known risk factor of cardiovascular diseases (CVD). Statins are well known and proven drugs for the lipid management of those wh...
Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
Background—
Homozygous familial hypercholesterolemia is a rare, serious disorder with a substantial reduction in low-density lipoprotein (LDL) receptor function, severe...
e0303 Significance of oxidised low-density lipoprotein in coronary atherosclerotic heart disease
e0303 Significance of oxidised low-density lipoprotein in coronary atherosclerotic heart disease
Objective
In this study, control group are people with normal coronary arteries. This study is to discuss the relationship between LDL, OX-LDL and control group, ...
Cumulative LDL-C Burden and Incident Acute Coronary Syndrome in Type 2 Diabetes
Cumulative LDL-C Burden and Incident Acute Coronary Syndrome in Type 2 Diabetes
Background: Low-density lipoprotein cholesterol (LDL-C) is a central modifiable driver of atherosclerotic cardiovascular disease, yet cardiovascular risk in type 2 diabetes mellitu...

